Mesenchymal stem cells in arthritic diseases.

Arthritis Res Ther. 2008;10(5):223 Authors: Chen FH, Tuan RS Mesenchymal stem cells (MSCs), the nonhematopoietic progenitor cells found in various adult tissues, are characterized by their ease of isolation and their rapid growth in vitro while maintaining their differentiation potential, allowing for extensive culture expansion to obtain large quantities suitable for therapeutic use. These properties…

Stem cell transplantation in rheumatoid arthritis.

Autoimmunity. 2008 Dec;41(8):625-31 Authors: Snowden JA, Kapoor S, Wilson AG The therapeutic potential of high dose cytotoxic therapy and stem cell transplantation (SCT) in severe rheumatoid arthritis (RA) was originally supported by animal studies and serendipitous clinical cases where allogeneic and autologous procedures were shown to ameliorate and potentially cure the disease. Phase I and…

The pro-inflammatory immunological memory : twist1 as a marker for chronically activated T lymphocytes

Z Rheumatol. 2008 Dec;67(8):684-8 Authors: Albrecht I, Niesner U, Janke M, Radbruch A, Chang H State-of-the-art immunosuppressive therapies, though efficient in the treatment of rheumatic inflammatory disorders, in most cases do not provide a cure. Complete immunablation and the associated deletion of the reactive immunological memory followed by reconstitution of the “healthy” immune system from…

Current value of stem-cell transplantation in autoimmune diseases

Z Rheumatol. 2008 Dec;67(8):716-22 Authors: Kötter I, Schmalzing M, Henes J, Vogel W, Kanz L Transplantations of autologous or allogeneic stem cells from bone marrow or peripheral blood are preformed for the treatment of resistant autoimmune diseases. Data have been systematically collected since 1996. We describe the historical development of this procedure for autoimmune diseases,…

Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis.

Arthritis Rheum. 2008 Dec;58(12):3765-75 Authors: Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE OBJECTIVE: To evaluate the ability of SNX-7081, a novel small molecule inhibitor of Hsp90, to block components of inflammation, including cytokine production, protein kinase activity, and…

• Telomerase transduced osteoarthritis fibroblast-like synoviocytes display a distinct gene expression profile.

J Rheumatol. 2009 Jan;36(1):141-55 Authors: Sun Y, Mauerhan DR, Firestein GS, Loeffler BJ, Hanley EN, Gruber HE OBJECTIVE: To examine the differential gene expression in telomerase transduced osteoarthritis fibroblast-like synoviocytes (hTERT-OA 13A FLS) and telomerase transduced rheumatoid arthritis FLS (hTERT-RA 516 FLS) and test the hypothesis that longterm culture of hTERT-OA 13A FLS display a…

Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential.

Tissue Eng Part A. 2009 Jul;15(7):1579-89 Authors: Lombardo E, DelaRosa O, Mancheño-Corvo P, Menta R, Ramìrez C, Büscher D Human adipose-derived stem cells (hASCs) are mesenchymal stem cells with reduced immunogenicity and the capability to modulate immune responses. These properties make hASCs of special interest as therapeutic agents in the settings of chronic inflammatory and…

Chronic graft-versus-host disease presenting as bullous lesions

Actas Dermosifiliogr. 2008 Dec;99(10):803-7 Authors: del Pozo J, Garcìa-Silva J, Yebra-Pimentel MT Graft-vs-host disease is still the leading cause of morbidity and mortality in patients undergoing bone marrow transplantation. It is important to start treatment early to reduce the severity and consequences of this complication. Cutaneous lesions are often the presenting compliant of graft-vs-host disease…